MA49464A - TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES - Google Patents

TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES

Info

Publication number
MA49464A
MA49464A MA049464A MA49464A MA49464A MA 49464 A MA49464 A MA 49464A MA 049464 A MA049464 A MA 049464A MA 49464 A MA49464 A MA 49464A MA 49464 A MA49464 A MA 49464A
Authority
MA
Morocco
Prior art keywords
associations
corresponding processes
targeted drug
new compositions
drug rescue
Prior art date
Application number
MA049464A
Other languages
French (fr)
Inventor
Anton Bespalov
Hans J Moebius
Sreenivasarao Vepachedu
Original Assignee
Exciva GmbH
Sreenivasarao Vepachedu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW106129169A external-priority patent/TW201815387A/en
Application filed by Exciva GmbH, Sreenivasarao Vepachedu filed Critical Exciva GmbH
Publication of MA49464A publication Critical patent/MA49464A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA049464A 2017-05-04 2018-05-03 TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES MA49464A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
TW106129169A TW201815387A (en) 2016-08-26 2017-08-28 Compositions and methods thereof
US201862634162P 2018-02-22 2018-02-22
US201862636099P 2018-02-27 2018-02-27
US201862635554P 2018-02-27 2018-02-27
US201862636171P 2018-02-28 2018-02-28

Publications (1)

Publication Number Publication Date
MA49464A true MA49464A (en) 2020-04-29

Family

ID=65431106

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049464A MA49464A (en) 2017-05-04 2018-05-03 TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES

Country Status (13)

Country Link
EP (1) EP3618819A4 (en)
JP (2) JP7514078B2 (en)
KR (2) KR20200062078A (en)
CN (1) CN110831584B (en)
AU (2) AU2018261654A1 (en)
BR (1) BR112019022902A2 (en)
CA (2) CA3062452C (en)
IL (1) IL270326B2 (en)
MA (1) MA49464A (en)
RU (1) RU2760558C9 (en)
TW (1) TWI787260B (en)
WO (1) WO2018204713A1 (en)
ZA (1) ZA201908006B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011203A (en) * 2019-03-18 2022-09-07 Avanir Pharmaceuticals Inc Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine.
WO2020246143A1 (en) * 2019-06-06 2020-12-10 Jsr株式会社 Radiation-sensitive resin composition, resist pattern formation method, and compound
CN115667217A (en) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 Deuterated tryptamine derivatives and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
EP1986639A4 (en) 2006-02-03 2010-04-28 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders
EP2162135A4 (en) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP6495191B2 (en) 2013-03-07 2019-04-03 マインドラブ・エルエルシー Analgesic combinations and their use
JP2016516202A (en) 2013-03-15 2016-06-02 キネメッド， インコーポレイテッド Biomarker
EP3503879A4 (en) * 2016-08-26 2020-04-29 EXCIVA GmbH Compositions and methods thereof

Also Published As

Publication number Publication date
CA3062452A1 (en) 2018-11-08
AU2021215274B2 (en) 2022-11-03
ZA201908006B (en) 2021-04-28
IL270326B2 (en) 2023-02-01
CA3062452C (en) 2023-10-24
RU2760558C9 (en) 2022-02-22
EP3618819A1 (en) 2020-03-11
IL270326A (en) 2018-05-03
KR20210130827A (en) 2021-11-01
WO2018204713A1 (en) 2018-11-08
BR112019022902A2 (en) 2020-05-19
CN110831584B (en) 2023-03-10
JP2023143940A (en) 2023-10-06
TWI787260B (en) 2022-12-21
RU2019137004A (en) 2021-06-04
KR102444803B1 (en) 2022-09-19
EP3618819A4 (en) 2021-01-20
CA3138116A1 (en) 2018-11-08
AU2018261654A1 (en) 2019-11-14
KR20200062078A (en) 2020-06-03
RU2760558C2 (en) 2021-11-29
JP2020518617A (en) 2020-06-25
JP7514078B2 (en) 2024-07-10
IL270326B (en) 2022-10-01
AU2021215274A1 (en) 2021-09-02
CN110831584A (en) 2020-02-21
RU2019137004A3 (en) 2021-06-04
TW201842902A (en) 2018-12-16

Similar Documents

Publication Publication Date Title
MA49858A (en) COMPOUNDS, COMPOSITIONS AND PROCESSES
MA50063A (en) COMPOUNDS, COMPOSITIONS AND PROCESSES
BR112018003110A2 (en) therapeutic nanoparticles comprising a therapeutic agent and methods of manufacturing and using them
DK3258939T3 (en) NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF
DK3705488T3 (en) NEUROACTIVE STEROIDS, COMPOSITIONS AND USE THEREOF
DK3297605T3 (en) TOPIC, PHARMACEUTICAL COMPOSITIONS
DK3580561T3 (en) HLA-BASED METHODS, COMPOSITIONS AND USES THEREOF
BR112016018521A2 (en) composition and kit.
CL2018000565A1 (en) Compounds derived from pyridinone dicarboxamide, bromodomain inhibitors; pharmaceutical composition; pharmaceutical combination; Useful in the treatment of autoimmune, inflammatory, viral and cancer diseases, among others.
DK3223796T3 (en) PHARMACEUTICAL COMPOSITIONS, MANUFACTURING AND USES
MA49633A (en) AGENTS, USES AND TREATMENT METHODS
MA47516A (en) PHARMACEUTICAL COMPOSITION
MA49464A (en) TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES
DK3383397T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRIN, TENOFOVIRDISOPROXILFUMARAT AND LAMIVUDIN
CL2020000973A1 (en) Compositions and procedures for the treatment of diffuse large b-cell lymphoma.
DK4023651T3 (en) OPTICALLY ACTIVE PYRANOCHROMENYLPHENOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
FR3024733B1 (en) THICKENING AGENT FOR AQUEOUS SYSTEMS, FORMULATIONS CONTAINING THE SAME AND USES THEREOF.
DK3424500T3 (en) PHARMACEUTICAL COMPOSITION INCLUDING FAMITINIB
DK3153163T3 (en) PHARMACEUTICAL COMPOUND CONTAINING 13 GLYCERIDES, FORMULATION AND USE THEREOF
MA56458A (en) MACITENTAN TABLET COMPOSITIONS, METHODS AND USES THEREOF
IT201700119847A1 (en) FAN STRUCTURE WITH AIR TREATMENT DEVICE.
TH1601003241A (en) Use of benzimidazole-proline derivatives
RU2014107124A (en) EXPLOSIVE COMPOSITION BASED ON HEXOGENE
IT201700028709A1 (en) ACIDS-5-CARBOSSAMIDE-2-THIOBARBITURIS AND THEIR USE AS MEDICATIONS
FR3046907B1 (en) ANTIFUNGAL AGENT, PROCESS AND COMPOSITION